News

Clinical Trial is Testing Stem Cells in Scleroderma

Richard Burt, MD, of Northwestern University is looking to harness the power of autologous, patient-derived stem cells for the treatment of systemic sclerosis. His previous work in a clinical trial with scleroderma motivated a new phase 3 clinical trial, entitled “…

Scleroderma Damage in Hands Better Assessed with Ultrasonographic Scans

New research on musculoskeletal ultrasound (MSUS) hand features in systemic sclerosis (SSc) or scleroderma and rheumatoid arthritis (RA) entitled “A comparative study between ultrasonographic hand features in systemic sclerosis and rheumatoid arthritis patients: Relation to disease activity, clinical and radiological findings” was recently published in the…

Clinical Phase I/II Pilot Trial Will Study New Therapy for Systemic Sclerosis

Children’s Hospital Los Angeles is recruiting Refractory Systemic Sclerosis Patients between 8 to 18 years of age for a Phase I/II pilot trial of the drug Campath-1H (ClinicalTrials.gov identifier: NCT01639573) to address whether prolonged administration of the drug can result in immunoablation. Campath-1H is a trade name…

Dartmouth Researchers Identify Various Biological Pathways That are Involved in Different Subsets of Systemic Sclerosis

Evidence is unclear about why some patients with systemic sclerosis (SSc) respond to treatment while others do not. However, a research team from Dartmouth was able to identify various biological pathways that are involved in different subsets of systemic sclerosis. Results from the research were published in two articles: the…